Blood Pressure Disorders Drug Development Pipeline Review, 2018 – ResearchByMarkets.com

PUNE, India, September 07, 2018 /ResearchByMarkets/— Blood Pressure Disorders Drug Development Pipeline Review, 2018

This report provides an overview of the pipeline landscape for blood pressure disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hypertension, pulmonary arterial hypertension (PAH) and hypotension, and features dormant and discontinued products.

Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in the body and the condition of the kidneys, nervous system, and blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels.

Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically do not occur until high blood pressure has reached a severe stage. There are 253 products in development for this indication.

PAH is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). There are 92 products in development for this indication.

Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms include blurred vision, dizziness, confusion, sleeplessness and weakness. Pipeline activity is much lower for hypotension than for hypertension or PAH with only seven products in development for this indication.

Molecular targets acted on by products in development for blood pressure disorders include angiotensin receptors, tyrosine protein kinases and phosphodiesterases. Companies operating in this pipeline space include Gmax Biopharm, Actelion Pharmaceuticals and Theravance Biopharma.

REQUEST A SAMPLE REPORT:
https://www.researchbymarkets.com/sample-request/33713

Scope

– Which companies are the most active within the pipeline for blood pressure disorders?
– Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
– What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

– Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
– Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
– Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
– Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.

BUY THIS REPORT ONLINE:
https://www.researchbymarkets.com/paynow/33713

Companies Mentioned:
A1M Pharma AB
Acceleron Pharma Inc
Ache Laboratorios Farmaceuticos SA
Actelion Pharmaceuticals Ltd
Aerogen Ltd
Anavex Life Sciences Corp
AnGes Inc
Arena Pharmaceuticals Inc
Ascendia Pharmaceuticals LLC
Ascendis Pharma A/S
AVEO Pharmaceuticals Inc
Bayer AG
BCO Pharma Ltd
Bial – Portela & Ca SA
Bioblue Technologies Inc
Biogen Inc
Biolab Farmaceutica Ltda
BioRestorative Therapies Inc
Boryung Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
Camurus AB
Capricor Therapeutics Inc
Celsion Corp
Celtaxsys Inc
Cerecor Inc
Chiesi Farmaceutici SpA
Chong Kun Dang Pharmaceutical Corp
Chugai Pharmaceutical Co Ltd
CJ HealthCare Corp
Complexa Inc
Corion Biotech Srl
Cumberland Pharmaceuticals Inc
D. Western Therapeutics Institute Inc
Daewon Pharm Co Ltd
Daewoong Co Ltd
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Denovo Biopharma LLC
Eli Lilly and Co
Esperion Therapeutics Inc
FunPep Co Ltd
Galectin Therapeutics Inc
Gemphire Therapeutics Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
H. Lundbeck AS
HanAll Biopharma Co Ltd
Hanmi Pharmaceuticals Co Ltd
Hypotension
Idorsia Pharmaceutical Ltd
Ildong Pharmaceutical Co Ltd
Innopharmax Inc
Insmed Inc
Insys Therapeutics Inc
Ionis Pharmaceuticals Inc
Japan Tobacco Inc
Jeil Pharmaceutical Co Ltd
Johnson & Johnson
KBP BioSciences Co Ltd
La Jolla Pharmaceutical Company
Leading BioSciences Inc
Lee’s Pharmaceutical Holdings Ltd
Les Laboratoires Servier SAS
LG Chem Ltd
LinXis BV
Liquidia Technologies Inc
MannKind Corp
Marina Biotech Inc
Merck & Co Inc
Mezzion Pharma Co Ltd
N4 Pharma Plc
Nippon Shinyaku Co Ltd
Nissan Chemical Industries Ltd
Northern Therapeutics Inc
Novartis AG
Omeros Corp
Orion Corporation
Peloton Therapeutics Inc
Pfizer Inc
PhaseBio Pharmaceuticals Inc
Pulmokine Inc
Pulmonary Arterial Hypertension
Quantum Genomics SA
Reata Pharmaceuticals Inc
Relief Therapeutics Holding AG
Relypsa Inc
Renova Therapeutics Inc
Respira Therapeutics Inc
Reviva Pharmaceuticals Inc
rEVO Biologics Inc
Roivant Sciences Ltd
Rottapharm Biotech Srl
Sanofi
Sarfez Pharmaceuticals Inc
Serodus ASA
Shanghai Pharmaceutical Co Ltd
SJT Molecular Research SL
SteadyMed Therapeutics Inc
Suda Pharmaceuticals Ltd
Sumitomo Dainippon Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
Takeda Pharmaceutical Co Ltd
Target Medicals LLC
The Medicines Company
Theracos Inc
Theravance Biopharma Inc
Toray Industries Inc
TrioxBio Inc
United Therapeutics Corp
Vascular BioSciences
VG Life Sciences Inc
Vicore Pharma AB
Vivus Inc
XuanZhu Pharma Co Ltd
Yuhan Corp

Get in touch with us:
ResearchByMarkets.com
Ritesh Tiwari, Director
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com/aboutus

 

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.